Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 3Congenital Abnormalities 3Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × Podophyllotoxin × Clear all
NCT00958022 2017-06-22

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

University of Pittsburgh

Phase 1 Terminated
7 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡